Rest of the world factor VIII deficiency treatment Market, By Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), Desmopressin), By Distribution Channel (Hospital Pharmacies, Reta

Rest of the world factor VIII deficiency treatment Market, By Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologic (Hemlibra), Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This may result in both spontaneous bleeding and bleeding after injuries or surgery. Blood contains a variety of clotting proteins that can aid in stopping bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The quantity of factors in a person's blood determines the severity of their hemophilia. The likelihood of bleeding, which can cause serious health issues, increases as the amount of the factor decreases. Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. This change or mutation can prevent the clotting protein from working properly or be missing altogether

Market Dynamics

Increase in the government and non-government organizations initiatives to improve access to affordable hemophilia treatment options. Rising incidences and prevalence of hemophilic disorder are expected to boost the growth of the market over the forecast period which leads to product launches in the market by the key players, to fulfill the unmet need of the market. Favorable regulatory scenarios and guidelines for product launches and treatment are other leading factors that are expected to propel the growth of the market over the forecast period. An increase in the research and development activities by key market players to develop novel hemophilia treatment options is further expected to drive market growth for the forecast period. For instance, on April 4, 2023, Sanofi S.A., a multinational pharmaceutical and healthcare company, announced the positive result of their phase-III clinical trials using fitusiran, a drug candidate used to treat hemophilia-A in adults.

Key features of the study:

• This report provides in-depth analysis of the rest of the world factor VIII deficiency treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new Product Type launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the rest of the world factor VIII deficiency treatment market based on the following parameters – company highlights, Product Types portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Baxter, Biogen, Inc., Bayer AG, CSL Behring, Ferring B.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Kedrion, and Novo Nordisk A/S
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product type launches, type up-gradation, market expansion, and marketing tactics
• The rest of the world factor VIII deficiency treatment market report caters to various stakeholders in this industry including investors, suppliers, product type manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the rest of the world factor VIII deficiency treatment market

Detailed Segmentation:

• Rest of the World Factor VIII Deficiency Treatment Market, By Product Type:
• Plasma Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Biologic (Hemlibra)
• Desmopressin
• Rest of the World Factor VIII Deficiency Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Rest of the World Factor VIII Deficiency Treatment Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Baxter*
• Company Highlights
• Product Types Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Biogen, Inc.
• Bayer AG
• CSL Behring
• Ferring B.V.
• F.Hoffmann-La Roche AG
• Pfizer, Inc.
• Kedrion
• Novo Nordisk A/S

“*” marked represents similar segmentation in other categories in the respective section.